SCHEMBL25197263

SCHEMBL25197263

CCn1nnc2ccc(-c3c[nH]c4nc(NC5CCN(C)CC5)ncc34)cc21

nearest known ligand 0.46

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ DYRK1A Q13627 3/20 0.46
▸ DYRK1B Q9Y463 2/20 0.46
▸ TDO2 P48775 12/20 0.44
▸ CLK2 P49760 1/20 0.43
▸ CLK3 P49761 1/20 0.43
▸ RET P07949 1/20 0.43
▸ MAPK7 Q13164 1/20 0.39
▸ JUN P05412 1/20 0.39
▸ CDK2 P24941 1/20 0.39
▸ MAPK8 P45983 1/20 0.39
▸ MAPK9 P45984 1/20 0.39
▸ IL2 P60568 1/20 0.39
▸ MAP4K1 Q92918 1/20 0.39
▸ TNIK Q9UKE5 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30348658 1.00 DYRK1A (0.46) DYRK1ADYRK1BTDO2CLK2CLK3
SCHEMBL25220651 0.90 DYRK1A (0.48) DYRK1ADYRK1BTDO2CLK2CLK3
SCHEMBL30348435 0.90 DYRK1A (0.48) DYRK1ADYRK1BTDO2CLK2CLK3
SCHEMBL25204091 0.90 TDO2 (0.48) DYRK1ATDO2CLK2RETCDK2
SCHEMBL30347404 0.90 TDO2 (0.48) DYRK1ATDO2CLK2RETCDK2
SCHEMBL25215195 0.88 TDO2 (0.45) DYRK1ATDO2CLK2CLK3RET
SCHEMBL25158118 0.88 TDO2 (0.43) DYRK1ADYRK1BTDO2CLK2CLK3
SCHEMBL25195580 0.88 TDO2 (0.45) DYRK1ATDO2CLK2CLK3RET
SCHEMBL25215193 0.88 TDO2 (0.45) DYRK1ATDO2CLK2CLK3RET
SCHEMBL25265919 0.88 TDO2 (0.45) DYRK1ATDO2CLK2CLK3RET

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250129104-A1 7H-PYRROLO[2,3-D]PYRIMIDINES AND PREPARATION AND USES THEREOF TENARX, INC. 2025-04-24 — — US claimed
US-20230167133-A1 7H-PYRROLO[2,3-D]PYRIMIDINES AND PREPARATION AND USES THEREOF VICKERS VENTURE FUND VI PTE. LTD. (SG) 2023-06-01 — — US claimed
US-20230167133-A1 7H-PYRROLO[2,3-D]PYRIMIDINES AND PREPARATION AND USES THEREOF VICKERS VENTURE FUND VI PTE. LTD. (SG) 2023-06-01 — — US disclosed
US-20230167133-A1 7H-PYRROLO[2,3-D]PYRIMIDINES AND PREPARATION AND USES THEREOF VICKERS VENTURE FUND VI PTE. LTD. (SG) 2023-06-01 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230167133-A1 7H-PYRROLO[2,3-D]PYRIMIDINES AND PREPARATION AND USES THEREOF DYRK1A, DYRK1B, DYRK2 DYRK1A 1/4885DYRK1B 2/4885TDO2 539/4885
US-20250129104-A1 7H-PYRROLO[2,3-D]PYRIMIDINES AND PREPARATION AND USES THEREOF DYRK1A, DYRK1B, DYRK2 DYRK1A 1/4885DYRK1B 2/4885TDO2 539/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback